Perspectives in psychopharmacological neuroimaging

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2533-2534

  Fusar Poli, Paolo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; ENDOCANNABINOID; GLUTAMIC ACID; MOOD STABILIZER; NEUROLEPTIC AGENT;

BIPOLAR DISORDER; BRAIN; BRAIN ELECTROPHYSIOLOGY; COGNITION; DIFFUSION TENSOR IMAGING; EDITORIAL; ELECTROENCEPHALOGRAM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; MENTAL DISEASE; MOOD DISORDER; MYELINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DEPRIVATION; WHITE MATTER;

BRAIN; DIAGNOSTIC IMAGING; HUMANS; MENTAL DISORDERS; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 69249084515     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957492     Document Type: Editorial

References (9)

1. Smieskova R, Fusar-Poli P, Allen P, Bendfeldt K, Stieglitz RD, Drewe J, Radue EW, McGuire PK, Riecher A, Borgwardt SJ. The Effects of Antipsychotics on the Brain: What have We Learnt from Structural Imaging of Schizophrenia? - A Systematic Review. Curr Pharm Des 15(22): 2535-2549.
2. Howes OD, Egerton A, Allan V, McGuire P, Stokes P, Kapur S. Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. Curr Pharm Des 15(22): 2550-2559.
3. Di Giorgio A, Sambataro F, Bertolino A. Functional Imaging as a Tool to Investigate the Relationship between Genetic Variation and Response to Treatment with Antipsychotics. Curr Pharm Des 15(22): 2560-2572.
4. Korostenskaja M, Kahkonen S. What do ERPs and ERFs Reveal About the Effect of Antipsychotic Treatment on Cognition in Schizophrenia? Curr Pharm Des 15(22): 2573-2593.
5. Stone JM. Imaging the Glutamate System in Humans: Relevance to Drug Discovery for Schizophrenia. Curr Pharm Des 15(22): 2594-2602.
6. Bhattacharyya S, Crippa JA, Martin-Santos R, Winton-Brown T, Fusar-Poli P. Imaging the Neural Effects of Cananbinoids: Current Status and Future Opportunities for Psychopharmacology. Curr Pharm Des 15(22): 2603-2614.
7. Whalley HC, Steele JD, Mukherjee P, Romaniuk L, McIntosh AM, Hall J, Lawrie SM. Connecting the Brain and New Drug Targets for Schizophrenia. Curr Pharm Des 15(22): 2615-2631.
8. Brambilla P, Bellani M, Yeh P-H, Soares J.C. Myelination in Bipolar Patients and the Effects of Mood Stabilizers on Brain Anatomy. Curr Pharm Des 15(22): 2632-2636.
9. Benedetti F, Smeraldi E. Neuroimaging and Genetics of Antidepressant Response to Sleep Deprivation: Implications for Drug Development. Curr Pharm Des 15(22): 2637-2649.